PTEN蛋白在前列腺癌组织中的表达及其临床意义

Expression of PTEN in Prostate Cancer and Its Clinical Significance

目的研究PTEN蛋白在前列腺癌组织中的表达及其临床意义。方法免疫组化S-P法测定29例前列腺癌(Pca)与20例前列腺增生(BPH)组织切片中PTEN蛋白的表达。结果 20例BPH中18 例(90．0％)、29例Pca中12例(41．4％)PTEN有不同程度表达,差异有显著性(P<0．05)。Pca中Gleason评分2～4分与5～7分两组间表达无差异(P>0．05),但此两组与8～10分组比较均有显著性差异(P<0．01);高分化与低分化组间表达有显著差异(P<0．01);临床A、B期与C、D期表达差异性显著(P<0．01)。Spearman等级相关分析PTEN蛋白在前列腺癌中的表达随肿瘤进展而降低。结论将PTEN作为诊断并预测Pca进展的肿瘤标记物有一定的临床意义。

Objective To study the expression of PTEN in prostate cancer and its clinical significance. Methods PTEN protein expression of 29 prostate cancers（Pca） and 20 benign prostatic hyperplasia samples were analysed by immunohisochemical staining. Results The positive rate of PTEN was 41.4%（12/29）in Pca and 90% （18/20） in BPH（P 〈0.05）. In the Gleason score groups the positive rate of PTEN differences were significant except the group between 2-4 score and 5-7 score.The differences were also significant between highly and poorly differentiated cancers. The positive rate of PTEN in A, B stage and in C, D stage were 77.8%（7/9） and 25%（5/20）（P 〈0.01） respectively.The expression of PTEN between Pca and clinical factors was negatively correlated in Spearman＇ s rank correlation analysis. Conclusion PTEN can serve as a tumor marker to diagnose and prognose the development of Pca.